Shanghai Fosun Omni Pharma Execs On The Market For Inhalation Products In China: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
Shanghai Fosun Omni Pharmaceutical was founded in 2006 as a joint venture between two former principal R&D leaders from Ivax/Teva and Shanghai Fosun Pharmaceutical, a leading pharmaceutical enterprise in China. Shanghai-based Omni's CEO Kai Zhang and Chief Operating Officer Shaochuan Zeng, the former leaders from Ivax/Teva, spoke with PharmAsia News' Shanghai bureau about their operation and the market for inhalation products in China.
You may also be interested in...
China’s Fosun Pharma Targets $650 Million IPO With Prudential Insurance As Cornerstone Investor
China’s largest non-state-owned pharma company Fosun Pharma commenced an initial global offering in Hong Kong, and nearly half of the money raised will be used for M&A. But the $650 million expected to be raised is much smaller than the rumored $800 million.
China’s Fosun Pharma Targets $650 Million IPO With Prudential Insurance As Cornerstone Investor
China’s largest non-state-owned pharma company Fosun Pharma commenced an initial global offering in Hong Kong, and nearly half of the money raised will be used for M&A. But the $650 million expected to be raised is much smaller than the rumored $800 million.
China's Largest Private Pharma Company Fosun Pharma Targets Biosimilar Market, With Sights On Becoming The Next Teva
SHANGHAI - China's largest private integrated healthcare company Shanghai Fosun Pharmaceutical Co. Ltd. will focus on gaining more market share in China with its branded generic business and branded traditional Chinese medicines, the company said during China's first ever Biotechnology Industry Organization conference held in Shanghai